Revised SPC: Buvidal (buprenorphine) prolonged-release solution for injection

SPC now warns of the risk of serotonin syndrome when used in conjunction with other serotonergic agents, such as MAO inhibitors, SSRIs, SNRIs or tricyclic antidepressants. If suspected, dose reduction or discontinuation of therapy should be considered depending on severity.

Source:

electronic Medicines compendium